Suzuki, I agree with you that the Adapt IP is also in the mix. I would love to hold onto the Adapt tech for mitral valve replacement. Sell the company’s TAVR tech to one of the big techs but hold onto the IP for the mitral valve area. This may be naive of me but if the big tech want the lot then WP should demand an extra $1b for the mitral potential which will rival the AV area in coming years.
Ann: Five TAVR Patients Successfully Implanted With DurAVR Valve, page-109
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.00 |
Change
0.000(0.00%) |
Mkt cap ! $295.9M | |||
| Open | High | Low | Value | Volume |
| $14.10 | $14.41 | $13.73 | $535.0K | 38.28K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 935 | $14.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.20 | 60 | 1 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |